Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

Moderna MRNA announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 vaccine, Spikevax, for use in children aged six months to 11 years, who ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.('Fosun Pharma', Stock Code: 600196.SH; 02196 ...

Comirnaty remains available to 12 to 15 year old folks under the EUA but there’s no reason to believe that full approval for that age group won’t eventually come.

However, its language does not imply there are no Comirnaty doses available in the U.S.—merely that there were not enough vaccines for those aged 16 and above.

Comirnaty was announced in December when the European Commission issued conditional marketing authorization for the vaccine, but the FDA doesn't allow the use of trade names for drugs until ...

Referring to COVID-19 vaccines by their brand names, an article headline misleads about their availability. "Few, If Any, Doses of Spikevax or Comirnaty Available in United States, Despite FDA ...

Comirnaty, as it's known, is the official, brand name for Pfizer and BioNTech's COVID-19 vaccine. The Food and Drug Administration this week gave full approval to the vaccine for people 16 and older.